Objective: To assess whether shared medical appointments (SMAs) for neuromuscular patients represent a way of using clinicians' time efficiently without compromising quality of care for patients.
Time is a precious resource in the context of patient care. 1 Patients hope to find attentive concern on the part of the clinician. On the other hand, in the interest of cost control, less rather than more time per patient is available. The fact that productivity gains in health care do not match those in other areas is an important factor contributing to the rise in health care costs. 2 The resulting increase in time pressure is not always experienced in the same way. Clinicians who became patients realized how time can be experienced differently. 3 Recognizing these developments in our own department, we wondered whether shared medical appointments (SMAs) (where multiple patients and their partners with the same diagnosis are seen by the neurologist at the same time) might help to resolve this problem. In a way, this creates more clinician time for the patient, although not exclusively for him or her individually. Also, the patient may benefit from knowledge and experiences of other patients, contributing to a decrease in resource utilization. 4, 5 To be sure, there is a tradeoff, since some patients may prefer not to discuss certain issues in the presence of others. We evaluated this approach in a randomized controlled trial (RCT). 6 In this complementary article, we report the results on resource use and quality of life. In a decision analytic model, we explored under which conditions SMAs for this patient population might qualify as an efficient and effective option.
METHODS Standard protocol approvals, registrations, and patient consents. This RCT was approved by the regional medical ethics committee and written informed consent was obtained from all participants. The trial is registered with the Dutch Trial Register (www.trialregister.nl) as NTR1412.
Study design. The study comprises an economic evaluation from the health care perspective and was conducted in parallel with an RCT. The methods and results pertaining to the clinical effectiveness of the RCT have been described in detail elsewhere. 6, 7 In brief, we conducted an RCT with a 6-month follow-up where patients with neuromuscular disease (NMD) were randomized to either an SMA or an individual appointment with one of the 2 participating neuromuscular neurologists (B.G.M.v.E., G.D.) at the outpatient clinic of the Neurology Department of the Radboud University Medical Centre.
The primary research question was to evaluate whether a single SMA is more cost-effective for patients with chronic neuromuscular disorders as compared to individual medical appointments.
The secondary research questions were to analyze under which conditions SMAs for patients with NMD qualify as an efficient and effective alternative to individual appointments and what effect SMAs have on the productivity of participating neurologists.
This study provides Class III evidence on whether SMAs are more cost-effective than individual appointments for patients with NMDs.
Participants. Patients were identified through the Computer
Registry of All Myopathies and Polyneuropathies (CRAMP), the Dutch database of patients with NMD, and recruited between March 2009 and March 2011. 8 Patients were eligible when they were diagnosed with one of the selected chronic NMDs (table 1) , were over 18 years of age, were currently in the care of our department, and had not seen their neurologist 6 months prior to study commencement. Patients were recruited from the practice of the study neurologists (B.G.M.v.E., G.D.) as well as from colleague neurologists of our department. Exclusion criteria were severe hearing problems or insufficient command of the Dutch language. 7 Eligible patients were invited to participate together with their partners or chief informal caregiver.
Randomization. Patient randomization (1:1) was computergenerated (by dedicated software), concealed, and balanced for diagnoses. Due to the nature of the intervention, physicians and participants could not be blinded to group assignment, but the statistician who conducted the analyses was blinded to treatment allocation.
Intervention. Patients and partners randomized to the SMA group were invited to attend an SMA of 1.5-2 hours as a substitute for their regular annual visit. During an SMA, 1 of 2 specialist neurologists (either B.G.M.v.E. or G.D.) saw 5-8 patients with the same diagnosis and their partners simultaneously, addressing the same topics that are commonly covered during the yearly follow-up appointment. The neurologist was supported by a group mentor who facilitated the group process by fostering interaction between patients and partners and by managing time. Both neurologists and the group mentor had received training in conducting SMAs prior to the study. Participants randomized to the control group were seen individually by one of the participating neurologists (B.G.M.v.E. or G.D.) during their regular annual 20-to-30-minute appointment. For both intervention groups, care was tailored to the needs of the patients and their partners. Prescriptions, referrals, and medical record-keeping were as usual.
Outcome measures. Utilities were evaluated by the EuroQol EQ-5D index scale for patients, a standardized instrument designed to determine health-related quality of life in terms of quality-adjusted life-years (QALYs). 9 To measure the use of resources, the following items from the Client Service Receipt Inventory 10 were included: visits to a general practitioner, medical specialist, physiotherapist, occupational therapist, psychologist, psychiatrist, or social worker; hospital admissions; medication; home care and domestic help.
Outcome measures were obtained through self-reported questionnaires unless stated otherwise. Participants received these by mail at home 4 weeks before and 1, 12, and 24 weeks after the intervention. Severity of disease according to the modified Rankin Scale was established by physicians during the appointments.
Valuation of the cost items. Costs were calculated by multiplying volumes of resources by the cost price per resource unit (table 2) . Cost prices were based on the Dutch guidelines for economic evaluation in health care unless stated otherwise.
11
Domestic help was quantified in hours worked, adopting national average hourly wage rates for domestic cleaners. All prices were converted to the year 2011 by means of the Dutch consumer price index and expressed in euros (at which time 1 euro was equivalent to British £0.85 and USD $1.31). 12 Intervention costs. Since no unit cost price was available for SMAs, we calculated SMA cost price on the basis of the actual time spent by the consultant neurologist and group mentor (a specialist nurse or equivalent). Cost prices of the health professionals' time were based on the Dutch guidelines for economic evaluation in health care and converted to 2011 corresponding with the valuation of the cost items. 11 No adjustments were made for the number of patients per SMA since this did not affect its organization or duration.
Statistical analysis. Descriptive statistics were used to generate baseline participant characteristics. Participant data were included for analysis when at least the baseline and 1 effect measurement was available. Remaining missing patient data on the volumes of resources used and QALYs were imputed with multiple imputation techniques. 13 Imputation was executed 5 times and the weighted means of cost variables and effects over the follow-up time were calculated. QALYs were calculated from baseline to follow-up (6-month periods) using the area under the curve method and compared with a t test. Analyses were conducted on the basis of the intention-to-treat principle. A p value of ,0.05 was regarded as significant and SPSS was used to conduct the analyses of total costs and QALYs.
Probabilistic decision model. To compare the cost-effectiveness of an SMA with an individual appointment, a probabilistic decision model was developed. The model consisted of 2 main branches, SMA and individual appointment, each allowing for the probability that a patient was seen by his own neurologist or not. (See figure e-1 on the Neurology ® Web site at Neurology.org for a schematic figure of the model structure.) Model parameters for expected costs (in euros) and effects (in QALYs) as well as number of patients per SMA were extracted from the results of Table 2 Cost variables, resources used, mean price per unit, and average costs per patient for the shared and the individual appointment groups 
of incremental cost and effectiveness values from n 5 1,000 iterations. The probability that an SMA is cost-effective was calculated using a willingness-to-pay of €80,000.00 per QALY, a threshold suggested by the Council for Public Health and Health Care of The Netherlands.
14 The impact of model parameters on the ICER were explored in 1-way and 2-way sensitivity analyses. TreeAge Pro and Microsoft Excel were used to conduct the decision modeling.
RESULTS Participants. In total, 272 patients were included in the study, of whom 143 were randomly assigned to the SMA group and 129 to the individual appointment group. For 37 patients, fewer than 2 measurements were available, resulting in a total of 235 datasets for analysis. The patients in the 2 groups were similar at baseline with respect to most variables (table 1). In the SMA group, slightly more patients were diagnosed with myotonic dystrophy type 1, fewer patients were seen by their treating neurologist, and slightly more patients reported comorbidity. These differences were corrected for in the statistical analyses.
Outcome. Volumes of resource use, unit cost prices, and average costs for both groups are presented in table 2. The pooled average cost of resources cumulated over the 6-month follow-up period was €1,317.44 (range €104.50-€8,846.16) per patient for the SMA group and €1,646.89 (range €131.71-€16,221.05) for the individual appointment group. The mean QALYs over the 6-month follow-up period for the SMA group was 0.69 (SE 0.14) and for the individual appointment group 0.74 (SE 0.16).
Monte Carlo modeling. A Monte Carlo simulation resulted in an incremental loss of 0.05 QALYs and a €48 reduction in costs for the 6-month follow-up period for the SMA/individual appointment contrast. In other words, for 1 QALY lost, health care could gain €960 per patient when SMAs would be implemented (ICER 5 €2960.00; 95% confidence interval €234,600.00, €36,800.00). The probability that SMAs are more cost-effective than individual visits was 39% at a willingness-to-pay of €80,000 (figure 1).
Sensitivity analysis. Costs appeared significantly influenced by the number of patients per SMA and the proportion of patients seen by their treating neurologist. One-way sensitivity analysis of number of patients per SMA vs expected costs resulted in a threshold value of 6.2 patients (figure 2). Two-way sensitivity analyses of number of patients and probability of being seen by the treating neurologist showed that group visits can be more cost-effective than individual visits provided that SMA groups comprise more than 6 patients and that 75% of the patients are seen by their treating neurologist (figure not shown).
Productivity. With a mean of 16 minutes (range 11-30), the neurologists spent less time per patient during the SMAs, given that the individual appointments lasted on average 25 minutes (range 20-30), as based on the actual attendance rates during the study period. Fewer than 8% of the patients required individual attention in addition to the SMA, a proportion that did not significantly influence the total time spent per patient in the intervention group. DISCUSSION Using data from our RCT in chronic neuromuscular patients in a Monte Carlo simulation, we did not find any substantial significant differences between single SMAs and single conventional individual visits in terms of costs per QALYs. On the other hand, sensitivity analyses showed that a single SMA was more cost-effective than an individual appointment when a group size of more than 6 patients was maintained and 75% of these patients were seen by their treating neurologist. We have shown that if the abovementioned prerequisites are met, SMAs have the possibility to improve productivity for this specific population without compromising quality of care. Shared appointments are different in nature from one-on-one visits and require a different approach and mindset from both the attending consultant and the patient, but as they provide patients an opportunity to share their knowledge and experiences as well as more time with their clinician, they may be more rewarding for both the patient and health professionals involved. However, we are aware that such advantages are largely speculative and need to be explored and substantiated in future studies. Although several studies have reported a decline in resource utilization associated with SMAs, our findings suggest that no such savings should be expected for the SMAs we evaluated during a 6-month followup. This may be attributed to our distinctive diagnosis groups; the previous studies included patients with more common diseases like diabetes and heart failure. 4, 5, 15 Attending a 90-minute group appointment with a neuromuscular neurologist and 6 to 8 peers could provide patients with a rare NMD with a wider variety of information and expertise, inducing more, instead of fewer, initial referrals. This is illustrated by the fact that resource utilization was significantly higher for patients who normally attend a general neurologist and during the study were seen by a specialized neuromuscular neurologist. Possibly underutilization of care is the case for several patients with a rare NMD and SMAs could make specialist care available to more patients. A potential decrease of resource utilization should be assessed in the light of fewer complications in the longer term.
We also offered the fact that we compared single SMAs with single individual appointments as an alternative explanation in our previous article; most other studies evaluated series of SMAs. 6, [16] [17] [18] Resource use might decrease after attending multiple SMAs, while patients gain knowledge over time and most referrals are being made during the first appointment.
Finally, although several authors emphasized that maintaining a sufficient SMA group size is important for both efficiency and interaction purposes, none have evaluated its impact. 17, 19 With our study we have shown that the cost-effectiveness of SMAs for NMD outpatients is particularly sensitive to SMA group size and to the proportion of patients seeing their treating neurologist. Incremental cost-effectiveness scatterplot of shared vs individual medical appointments
The incremental cost-effectiveness scatterplot includes a single set of points representing pairs of incremental cost and effectiveness values from the simulation results (n 5 1,000) relative to a baseline. The slope intersecting the x axis is the willingness-to-pay (WTP) threshold of €80,000. In addition to the WTP line, a 95% confidence ellipse is drawn in the incremental cost-effectiveness scatterplot. The graph can be divided into 4 quadrants: southeast, shared medical appointments (SMAs) are less costly and more effective (SMAs dominate); southwest, SMAs are less costly and less effective; northwest, SMAs are more costly and less effective (individual appointments dominate); northeast, SMAs are more costly and more effective. The probability of SMAs being considered more cost-effective than individual appointments was 39% at a WTP of €80,000. QALYs 5 quality-adjusted life-years.
We performed an economic evaluation alongside a sizeable RCT, the robust design of which enabled us to align the intervention to usual care and to reliably compare the cost-effectiveness of a single SMA to that of an individual appointment. 6 The wide range of neuromuscular disorders included in our cohort is reflective of clinical practice and enhances the generalizability of our results. Additionally, all missing volumes of resource use were imputed using multiple imputation techniques, which have been shown to be a reliable method for missing cost data. 20 Then again, opting for a societal point of view for this economic evaluation may have strengthened the results, although we conjectured that the effects would be negligible. When interpreting the results it is important to take into account that patients attending an SMA together could influence each other. This could result in clustering effects and overrate the effect of the SMAs. Also, the self-reported comorbidity rates at baseline were slightly higher in the SMA group. Correcting for this slight imbalance in the analysis did not affect the resource utilization in the 2 groups. Another limitation is the study period; the 6-month follow-up may have been too short a period to unveil differences in costs, as it is plausible to assume that the number of referrals for the patients attending SMAs will drop after the initial group visit.
On a broad scale, controlled studies comparing the economic benefits of health care innovations that promote self-management skills in patients with a neuromuscular disorder are limited and additional RCTs with longer follow-up periods are needed to determine their long-term cost-effectiveness. More specifically, the potential effect of SMAs on resource utilization could be higher for patients for whom curative treatment options are available alongside symptomatic treatment. This would be an interesting question for further studies in this area. Follow-up research should also investigate which (groups of) patients benefit most from SMAs and which variables, besides group size and the proportion of patients seeing their own neurologist, influence cost-effectiveness most.
Although we were unable to detect consistent significant differences in terms of costs per QALY between an SMA and an individual appointment for chronic neuromuscular patients within the scope of our investigations, our data provided evidence suggesting that in this population the economic impact of SMAs depends on group size and the proportion of patients being seen by their own neurologist.
These conditions will concurrently help increase the productivity of the consulting physician without compromising quality of care. This adds important data to our earlier results on the effectiveness of SMAs for neuromuscular patients. 6 Especially for rare chronic diseases such as NMDs, group visits could make high-quality outpatient care from a specialist neurologist available for more patients while at the same time empowering these patients and their partners or informal caregivers by reinforcing their selfmanagement skills. However, before SMAs can be more widely implemented, long-term effects on the costs and possible working mechanisms will need to be systematically explored and substantiated further. One-way sensitivity analyses of the costs for shared medical appointment group size Probability of being seen by the treating neurologist in the shared medical appointment (SMA) group: 0.75; probability of being seen by treating neurologist in the individual group: 0.90. Threshold value of €628.60 at 6.2 patients.
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